Amphastar Pharmaceuticals, Inc.: Form 10-K for the period ended Dec 31, 2016
Filed with the SEC on Mar 15, 2017 and accepted by EDGAR at Mar 14, 2017, 18:57 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2016-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2016-10-01 to 2016-12-31 | $63.5m | us-gaap:SalesRevenueNet |
| Cost of revenue | 12 months2016-01-01 to 2016-12-31 | $151.0m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2016-10-01 to 2016-12-31 | $20.0m | us-gaap:GrossProfit |
| Gross profit | 12 months2016-01-01 to 2016-12-31 | $104.2m | us-gaap:GrossProfit |
| Research and development | 12 months2016-01-01 to 2016-12-31 | $41.2m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2016-01-01 to 2016-12-31 | $15.7m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2016-01-01 to 2016-12-31 | $1.0m | us-gaap:InterestExpense |
| Income tax | 12 months2016-01-01 to 2016-12-31 | $4.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2016-10-01 to 2016-12-31 | −$2.7m | us-gaap:NetIncomeLoss |
| Net income | 12 months2016-01-01 to 2016-12-31 | $10.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2016-10-01 to 2016-12-31 | −$0.06 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 12 months2016-01-01 to 2016-12-31 | $0.22 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2016-10-01 to 2016-12-31 | −$0.06 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 12 months2016-01-01 to 2016-12-31 | $0.23 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2016-10-01 to 2016-12-31 | 46,104,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 12 months2016-01-01 to 2016-12-31 | 47,504,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Capital expenditure | 12 months2016-01-01 to 2016-12-31 | $21.4m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 12 months2016-01-01 to 2016-12-31 | $9.9m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2016-12-31 | $72.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2016-12-31 | $184.1m | us-gaap:AssetsCurrent |
| Total assets | At period end2016-12-31 | $427.7m | us-gaap:Assets |
| Current liabilities | At period end2016-12-31 | $60.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2016-12-31 | $98.5m | us-gaap:Liabilities |
| Long-term debt | At period end2016-12-31 | $36.0m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2016-12-31 | $329.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001297184-17-000007. Last ingested by Listed: Nov 6, 2026, 17:01 ET. Listed shows no prices and gives no investment advice.